Standard-dose RT Superior to High-dose in Patients with Stage III NSCLC Undergoing Chemo

Share this content:

CHICAGO—Standard-dose radiation therapy (RT) is superior to high-dose RT in terms of overall survival (OS) and local-regional control in patients undergoing chemotherapy for locally advanced stage III non-small cell lung cancer (NSCLC), results of a study reported at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.

“This is a critical study in the field of radiation oncology,” said ASCO President Sandra M. Swain, MD, FACP. “After a decade of research, we can finally close the chapter on the high-dose versus standard-dose therapy debate in lung cancer therapy, using evidence-based data to improve care for our patients.”

The phase 3 Intergroup trial randomly assigned 464 patients to treatment with standard- or high-dose RT with concurrent weekly paclitaxel 45 mg/m2 and carboplatin AUC (area under the curve) 2 and cetuximab 400 mg/m2 loading dose on day 1 followed by weekly doses of 250 mg/m2 or no additional therapy. 

Results showed the standard 60 Gy dose was safer and more effective than 74 Gy; patients on the high-dose arm had a 56% greater risk of death and a 37% increased risk of developing local failure. The high-dose arm was closed in June 2011 after an interim analysis showed it was not superior to the standard-dose arm. Use of the higher dose was based on results of phase 1 and 2 trials that suggested better outcomes.

“The biological reasons for failure of the high dose with respect to overall survival and local-regional control are not readily apparent,” said Jeffrey D. Bradley, MD, a professor of radiation oncology at the Washington University School of Medicine in St. Louis, MO. “Possible explanations are unreported toxicities, increased heart dose, extended therapy duration, grade 5 events, or likely a combination of these factors,” he added,  The difference between arms in OS was also not accounted for by protocol deviations.

A total of 419 patients were evaluable for analysis. Median follow-up was 17.2 months. Median OS for patients in the standard-dose arm was 28.7 months compared with 19.5 months for the high-dose arm; estimated 18-month OS rates were 66.9% and 53.9%, respectively (hazard ratio [HR], 1.56; 95% CI: 1.19-2.06; P=0.0007). The 18-month progression-free survival rate was 36.6% versus 26.3% (HR, 1.3; 95% CI: 1.04-1.63; P=0.0116). 

At 18 months, local recurrence rates were 34.3% in the high-dose arm versus 25.1% in the standard-dose arm (HR, 1.37; 95% CI: 0.99–1.89; P=0.0319); distant failure rates were 47.8% versus 42.4%, respectively.

The only significant difference in side effects was a slightly higher rate of esophagitis in the high-dose arm, 21% (7% in the standard-dose arm). Ten treatment-related deaths occurred in the high-dose arm compared with two in the standard-dose arm.

The investigators noted that the effect of cetuximab awaits further follow-up.

This research was supported by the National Cancer Institute and Eli Lilly and Company.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs